Many medium- and long-chain fatty acids have broad antimicrobial activity, yet their limited aqueous solubility hinders deployment in clinic. We’ve developed a patented amino-acid–fatty-acid pairing approach that renders these molecules water-dispersible for clinical-grade formulation, supporting a range of potential applications.
Learn more
Our key focus is developing an undecylenic acid-based formulation, Solexan™, as a therapy for shingles. Solexan™ has been FDA-registered as a topical antifungal so its safety profile is already established, allowing us to fast-track Solexan™ into efficacy trials. We have successfully completed a Phase I trial, validating the safety of Solexan™ in shingles patients, and are busily preparing for commencement of a proof-of-concept Phase II clinical trial.
Learn moreWe don’t want to stop at shingles. Every single day, more and more patients fall victim to infectious diseases and antimicrobial resistance (AMR) is making treatment difficult. New therapies are desperately needed to combat drug-resistant bacteria and new strains of micro-organisms to improve health outcomes for individuals and society at large. We’ve seen that our formulations of fatty acids have powerful activity against many bacterial-borne diseases like Impetigo, caused by Staphylococcus aureus.
Learn more